Ani Pharmaceuticals Stock News

Morgan Stanley lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 2.2% during the second quarter, Holdings Channel reports. The institutional investor owned 106,418 shares of the specialty pharmaceutical companys stock after selling 2,360 shares during the period. Morgan Stanleys holdings in ANI Pharmaceuticals were worth $3,730,000 as of its most recent filing with the []

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Thomas Haughey bought 2,500 shares of the companys stock in a transaction that occurred on Monday, December 6th. The shares were bought at an average cost of $39.38 per share, for a total transaction of $98,450.00. The transaction was disclosed in a document filed with the SEC, which is available []

Analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to announce sales of $58.25 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for ANI Pharmaceuticals earnings. The highest sales estimate is $61.00 million and the lowest is $55.50 million. ANI Pharmaceuticals posted sales of $57.25 million during the same quarter last []

Analysts expect ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) to report sales of $58.25 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for ANI Pharmaceuticals earnings. The lowest sales estimate is $55.50 million and the highest is $61.00 million. ANI Pharmaceuticals reported sales of $57.25 million during the same quarter last []

Brokerages forecast that ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will post earnings of $0.84 per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for ANI Pharmaceuticals earnings, with estimates ranging from $0.82 to $0.86. ANI Pharmaceuticals reported earnings of $0.80 per share during the same quarter last year, which suggests a positive []

Mesirow Financial Investment Management Inc. lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 36.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 12,277 shares of the specialty pharmaceutical companys stock after purchasing an additional 3,303 shares during the []

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey-based pharmaceutical company with development, manufacturing, and commercialization capabilities. Today marks a major milestone for ANI and the many patients who rely on our high-quality, cost-effective medications. With the completion of this acquisition, we bring on board a w

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Finan

The Federal Trade Commission (“FTC”) reached a settlement with generic drug companies ANI Pharmaceuticals, Inc. (“ANI”) and Novitium Pharma LLC (“Novitium”), as well as Novitium’s parent company, to resolve allegations that ANI’s acquisition of Novitium would cause future harm to competition in markets for two generic medications in violation of the FTC Act and the Clayton Act…... By: Cozen O''Connor

Related Stocks: SGC , ANIP , IHI , IYT , CMC , PSQ , T , GE , IJT , RDS.A , SHV , BMY ,

Squarepoint Ops LLC raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 57.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,732 shares of the specialty pharmaceutical companys stock after buying an additional 7,580 shares during the period. Squarepoint Ops LLCs holdings in []

Renaissance Technologies LLC lowered its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 41.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 67,379 shares of the specialty pharmaceutical companys stock after selling 47,823 shares during the period. Renaissance Technologies LLC owned approximately []

ANI Pharmaceuticals (NASDAQ: ANIP) recently announced that it recorded $52.1 million net revenues for its third quarter of 2021. However, this was roughly one million dollars less than what they rep

The company reported positive third-quarter earnings, and the FDA granted approval for its generic version of Acthar Gel.

ANI Pharmaceuticals, Inc. (ANIP) CEO Nikhil Lalwani on Q3 2021 Results - Earnings Call Transcript